Pipeline Data and Quarterly Report: BioNTech’s Next Two Hurdles After Shareholder Backing

BioNTech's AGM approvals pave way for leadership change, but investor focus is on upcoming ASCO data for Pumitamig. Stock nears 52-week low as revenue declines and oncology pivot urgency grows.

BioNTech has cleared the formalities, but the market is already looking past the annual general meeting to a pair of make-or-break events that will test the credibility of its oncology pivot. The stock remains stuck near its 52-week low, and investors are demanding evidence that the costly transformation is gaining traction.

On 15 May, 92% of the voting capital backed management at the virtual AGM, approving every resolution. The supervisory board was expanded from six to eight members, with Iris Löw-Friedrich and Susanne Schaffert, both seasoned in clinical development and oncology, joining the ranks. Helmut Jeggle was re-elected as chairman, and the mandates of Anja Morawietz and Rudolf Staudigl were extended. The refresh paves the way for a leadership succession that is already under way: Ugur Sahin and Özlem Türeci will step down from the executive board by the end of 2026 to take the helm of a new corporate entity, and BioNTech is actively searching for their replacements.

The real test, however, is scientific. From 29 May to 2 June, at the ASCO congress, BioNTech will present Phase 2 data from the ROSETTA-Lung-02 study, comparing its bispecific antibody Pumitamig plus chemotherapy against the established standard, pembrolizumab plus chemotherapy, in lung cancer. Previous Pumitamig results came from a Chinese population; the global dataset now needs to show a competitive edge. The stakes are high because BioNTech has already launched five new pivotal studies with Pumitamig in triple-negative breast cancer, MSS colorectal cancer, gastric cancer, and two lung cancer settings. Additional late-stage readouts are expected later in the year. In April 2026, the company also struck a clinical collaboration with Boehringer Ingelheim to test Pumitamig alongside Obrixtamig, an experimental DLL3/CD3 T-cell engager for small-cell lung cancer, with Boehringer taking the regulatory lead in the Phase 1b/2 study.

Financial results underscore the urgency of progress in the pipeline. First-quarter revenue slid to €118.1m from €182.8m a year earlier as the Covid vaccine business continues to shrink. BioNTech nevertheless held its full-year guidance and reiterated a 2026 revenue target of $2.3bn to $2.6bn. A $1bn share buyback programme, authorised for the next twelve months, is intended to signal confidence, but the cash cushion alone has not lifted sentiment. For 2024, the company reported total revenue of around €2.75bn and a net loss of €665m, reflecting heavy investment in mRNA oncology candidates and restructuring costs, including capacity adjustments and job cuts at its Gaithersburg, Maryland site.

The stock closed at €76.95 on Friday, down 2.22% on the day and 8.01% over the past month. It sits below both the 50-day moving average of €81.70 and the 200-day line of €86.94, with the 52-week low of €72.50 only 6% away. The 52-week high of €101.90 now looks distant.

Analyst opinions remain divided. Canaccord lowered its price target to $158 from $171 but maintained a buy rating, while Leerink Partners cut to $94, citing concerns over a separate cancer study. The consensus target of $118.44 points to theoretical upside, but the market is not pricing in that optimism yet.

The next concrete inflection point after ASCO arrives on 30 June, when BioNTech publishes its quarterly communication. Investors will be looking for signs of cost discipline and tangible pipeline milestones. Strong ROSETTA-Lung-02 data would validate the oncology shift and ease pressure on the stock; weak results would amplify doubts about both the science and the leadership transition. For now, all eyes are on two back-to-back windows that will define BioNTech’s near-term direction.